Navelbine (Vinorelbine Tartrate)

Vinorelbine tartrate, the active ingredient in Navelbine, is a Vinca alkaloid presented as a sterile injectable solution for intravenous use. It is employed in the treatment of certain advanced solid tumours, primarily non‑small cell lung cancer and metastatic breast cancer, in adult patients.

GNH USA supplies Navelbine as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Vinorelbine is a chemotherapy agent used in the management of solid tumours, particularly within the lung and breast cancer pathways.

Non‑small cell lung cancer: helps to inhibit tumour growth and improve disease control in advanced stages. Metastatic breast cancer: used to reduce tumour progression and extend survival. Combination chemotherapy regimens: incorporated to enhance antitumour activity when used with other cytotoxic agents in various solid tumours.

Vinorelbine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Neutropenia: reduced neutrophil count increasing infection risk. - Nausea and vomiting: gastrointestinal upset commonly reported. - Constipation: decreased bowel motility. - Alopecia: hair loss during treatment.

Serious or Rare Side Effects: - Severe neutropenia with febrile infection: potentially life‑threatening. - Hypersensitivity reactions: including rash, bronchospasm, or anaphylaxis. - Pulmonary toxicity: interstitial pneumonitis or fibrosis. - Peripheral neuropathy: nerve damage causing tingling or pain. - Cardiac arrhythmias: irregular heart rhythms requiring monitoring.

Vinorelbine requires careful monitoring and specific safety measures before and during therapy.

Monitor blood counts: perform regular complete blood counts to detect myelosuppression. Assess liver function: evaluate hepatic enzymes as the drug is metabolised hepatically. Evaluate pulmonary status: use caution in patients with pre‑existing lung disease. Avoid in severe renal impairment: dose adjustment may be necessary. Use with caution when combined with other myelosuppressive agents. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Vinorelbine can interact with several drug classes, necessitating vigilance.

Major Interactions (Avoid): - Concurrent myelosuppressive chemotherapy: may exacerbate bone‑marrow suppression. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase vinorelbine plasma levels. - Live vaccines: risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - Anticoagulants (e.g., warfarin): monitor coagulation parameters for bleeding risk.